+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiangiogenic treatment in metastatic urothelial cancer



Antiangiogenic treatment in metastatic urothelial cancer



Lancet. Oncology 13(8): 748-749




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051572110

Download citation: RISBibTeXText

PMID: 22819171

DOI: 10.1016/S1470-2045(12)70319-4


Related references

From AACR—urological cancer Antiangiogenic therapy works in metastatic urothelial cancer. Nature Reviews Clinical Oncology (formerly Nature Clinical Practice Oncology) 9(6): 307-307, 2012

Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology 2019, 2019

Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. Clinical Breast Cancer 8 Suppl 4: S151-S156, 2009

Treatment of metastatic cancer with the anticopper, antiangiogenic drug, tetrathiomolybdate. Journal of Investigative Medicine 47(7): 223A, 1999

Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clinical Colorectal Cancer 13(3): 135-144, 2015

Use of the CellSearch Circulating Tumor Cell Test for monitoring urothelial cancer: two case reports of metastatic urothelial cancer. Southern Medical Journal 101(4): 439-441, 2008

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clinical Cancer Research 6(1): 1-10, 2000

Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncology 2019, 2019

Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer. European Urology Focus 2(6): 642-649, 2017

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs and Aging 28(2): 83-91, 2011

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Journal of Clinical Investigation 122(5): 1832-1848, 2012

Treatment of metastatic urothelial cancer with paclitaxel and carboplatin. Annals of Hematology 73(SUPPL 2): A76, 1996

New drugs and new approaches for the treatment of metastatic urothelial cancer. World Journal of Urology 20(3): 158-166, 2002

Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. Future Oncology 14(26): 2683-2690, 2018

Treatment of metastatic urothelial cancer in the post-MVAC era. World Journal of Urology 19(2): 126-132, 2001